Opioid poisoning and the opioid toxidrome (emergency department diagnosis and management)

Opioid poisoning is the archetype of the receptor-mediated toxidrome: a patient who is obtunded, with pin-point pupils and a slow, shallow breathing pattern, is opioid-toxic until proven otherwise, and the reversible cause is naloxone. The Fellowship candidate must recognise the triad, titrate naloxone to adequate ventilation rather than to full consciousness, and never be caught by the long half-life of methadone or the serotonergic and pro-convulsant profile of tramadol. The danger is hypoxia from respiratory depression, and the danger of the antidote is precipitating acute withdrawal or a catecholamine surge. The candidate who empties a large naloxone bolus and walks away has failed both the patient and the topic.[1][2]

Definition and classification

An opioid is any compound, natural or synthetic, that produces its characteristic effects by agonism at the mu-opioid receptor. The opioid toxidrome is the predictable clinical syndrome of that agonism: central nervous system depression, miosis (pin-point pupils) and respiratory depression, with hypotension, hypothermia and reduced gastrointestinal motility as supporting features. The class spans the natural opium alkaloids (morphine, codeine), the semisynthetics derived from them (heroin or diamorphine, oxycodone, hydrocodone, buprenorphine), and the fully synthetic agents (fentanyl, pethidine or meperidine, methadone, tramadol, propoxyphene). The distinction that matters at the bedside is duration of action: the short-acting agents (heroin, morphine, fentanyl, most immediate-release oxycodone) re-narcotise only briefly after a naloxone bolus, whereas the long-acting agents (methadone, sustained-release oxycodone, the fentanyl patch) store drug in a deep compartment and re-sedate the patient hours later. Tramadol and pethidine stand apart because they are serotonergic and pro-convulsant as well as opioid, and buprenorphine is a partial agonist that complicates naloxone reversal. [1]

Epidemiology and risk factors

Opioid overdose is a leading cause of accidental and drug-related death globally, driven by prescription opioid exposure and, increasingly, by illicit fentanyl and its analogues. The risk of fatal poisoning is concentrated in three groups: the opioid-naive patient given a therapeutic dose (the postoperative patient, the elderly patient started on oxycodone, the child who finds a tablet), the opioid-tolerant patient whose supply changes (loss of tolerance after a period of abstinence — prison release, supervised detoxification, hospital discharge), and the long-acting or sustained-release user (methadone maintenance, the fentanyl patch, sustained-release morphine) in whom accumulation and delayed peak produce toxicity many hours after ingestion. Fentanyl has transformed the epidemiology because it is cheap, potent (approximately 100 times morphine by weight) and rapidly fatal: respiratory arrest can occur within minutes of exposure, and a proportion of overdose deaths now involve a fentanyl analogue the user never knew they had taken. Co-ingestion of alcohol, benzodiazepines or gabapentinoids multiplies the respiratory depressant effect and is present in a large fraction of fatal cases. Reduced tolerance and polysubstance use, not dose escalation alone, are the recurrent themes.[1]

Pathophysiology

Opioid toxicity is generated by agonism at the mu-opioid receptor, and the candidate must trace each clinical feature to the receptor and the site. Mu-receptor agonism in the ventrolateral medulla and the pre-Bötzinger complex — the brainstem respiratory pattern generator — abolishes the central chemoreceptor response to hypercapnia and blunts the peripheral response to hypoxia. The result is the lethal feature of the toxidrome: respiratory depression that falls on both the rate and the depth of breathing, so tidal volume and minute ventilation collapse together and the patient becomes hypoxaemic and hypercapnic. Mu-receptor activity in the Edinger-Westphal nucleus of the midbrain produces miosis by parasympathetic stimulation of the sphincter pupillae, giving the pin-point pupil (one to two millimetres) that is the signature of the syndrome; miosis is bilateral and reactive in pure opioid toxicity. Agonism at the locus coeruleus and the thalamus produces sedation and analgesia that deepen to coma, and at the nucleus tractus solitarius it produces bradycardia and hypotension through vagal tone. Histamine release from mast cells, particularly with morphine and meperidine, adds urticaria, bronchospasm and hypotension that are pharmacological rather than IgE-mediated, which is why true anaphylaxis to an opioid is rare but opioid-related flushing and wheeze are common.[2]

Clinical presentation

The opioid toxidrome is a triad, and the candidate must name all three components and their physiology. Central nervous system depression ranges from mild drowsiness and slurred speech through to deep coma; the Glasgow Coma Scale may be as low as 3 in the apnoeic patient. Miosis is the pin-point pupil of one to two millimetres, bilateral and reactive, and is present in the overwhelming majority of pure opioid overdoses — its absence should prompt a search for a co-ingestant, a mixed toxidrome or a structural lesion, though severe hypoxia or a fentanyl analogue may occasionally spare the pupils. Respiratory depression is the killing feature: both the rate (commonly four to eight per minute) and the depth (small tidal volumes) fall, the oxygen saturation drops, and the capnography shows a rising end-tidal carbon dioxide. The breathing pattern is slow and shallow, and the patient may be cyanosed and hypothermic. Supporting features are hypotension from vasodilatation and bradycardia, hypothermia, hyporeflexia, reduced bowel sounds and a palpably soft abdomen from reduced gut motility. Needle tracks, a fentanyl patch on the skin or tablet bottles in the belongings are circumstantial but decisive. [1]

The syndrome is modified by the agent. Fentanyl may produce chest-wall rigidity (wooden chest syndrome) that makes ventilation difficult even before naloxone is given, and its onset is within minutes. Methadone produces a prolonged coma with QT prolongation and torsades risk on the ECG. Tramadol and pethidine add a tremulous, agitated, clonus-positive serotonergic picture and a seizure risk that naloxone does not abolish. Buprenorphine, a partial agonist with high receptor affinity, may require higher cumulative naloxone doses to reverse.[2]

Differential diagnosis

The differential of the opioid toxidrome splits into two questions: what else causes a coma with miosis, and what else causes respiratory depression with a reduced conscious level. The pin-point pupil narrows the field dramatically — only a handful of conditions reproduce it. [1]

A practical rule: the patient who fails to respond to an adequate dose of naloxone (1.2 to 2 milligrams intravenously) either does not have a pure opioid overdose, has a co-ingestant or a structural lesion, or has taken a long-acting agent that has not yet fully reversed. Check a glucose, re-examine the pupils for asymmetry, and image if the picture is atypical. [1]

The toxidrome approach to the unknown overdose

When the agent is unknown, the Fellowship candidate abandons the agent-led search and works from the toxidrome — the cluster of vital signs, pupil size, secretions, bowel sounds and skin that fingerprints a receptor class. The unknown-overdose patient who is comatose with a reduced respiratory rate is managed by the same ABCDE pathway as the opioid overdose, but the diagnostic engine is the toxidrome, and the pupil is the single most discriminating sign. Miosis narrows the field to the opioid, the alpha-2 agonist (clonidine), the pontine lesion and the cholinergic syndrome; mydriasis points to the sympathomimetic (amphetamines, cocaine) or the anticholinergic (antihistamines, tricyclics, atropine); a mid-position or normal pupil points to the sedative-hypnotic group (benzodiazepine, alcohol, barbiturate, gabapentinoid). The candidate runs the four classical toxidromes in parallel and treats the one the bedside matches, never waiting for a drug level.[5]

The four classical toxidromes are the scaffold for the unknown overdose, and the candidate must be able to recite the vital-sign, pupil, secretion and gut pattern of each in under thirty seconds. [1]

Bedside assessment

The first assessment is resuscitative and is read in parallel with the airway. Establish airway patency — the obtunded opioid patient is at high risk of aspiration, and the left lateral position with suction protects the airway until naloxone works. Give high-flow oxygen to the cyanosed or desaturating patient, but recognise that the target is ventilation, not oxygenation alone: a patient saturated on a non-rebreather mask who is still hypercapnic and bradypnoeic needs naloxone, not more oxygen. Secure intravenous access and attach pulse oximetry, continuous capnography (the rising end-tidal carbon dioxide is the earliest objective sign of respiratory depression) and cardiac monitoring. Take the history from paramedics, family and the patient's own belongings: the agent, the route (intravenous, inhaled, transdermal, oral), the time of exposure, and any co-ingestants, with particular attention to benzodiazepines, alcohol, gabapentinoids and serotonergic drugs. The focused examination confirms miosis, the slow shallow breathing pattern, the soft silent abdomen, the needle tracks or transdermal patch, and excludes the mimic — check for asymmetry of the pupils, a focal neurological deficit or a Cushing response that points to a pontine lesion. A bedside glucose is checked immediately on every comatose patient. [1]

Investigations

Opioid poisoning is a clinical and naloxone-responsive diagnosis, and treatment is never delayed for investigation. The bedside glucose is the single mandatory point-of-care test, because hypoglycaemia is the great mimic of any coma and is rapidly reversible. A venous or arterial blood gas quantifies the hypoxaemia, the hypercapnia and the acidosis, and tracks the response to naloxone. The 12-lead ECG screens for methadone-driven QT prolongation and torsades risk, for the QRS widening of a co-ingested sodium-channel blocker (tricyclic, lamotrigine), and for the bradycardia of clonidine. A paracetamol level, a salicylate level and an ethanol concentration are sent on every deliberate self-harm overdose, because the opioid is frequently one component of a mixed ingestion. A creatine kinase screens for rhabdomyolysis in the prolonged-coma patient, and a chest radiograph identifies aspiration and the non-cardiogenic pulmonary oedema that complicates opioid and especially heroin overdose. A urine drug screen is confirmatory but rarely changes acute management; quantitative opioid levels are not useful in real time.[3][4]

Immediate management and resuscitation

The management is airway, oxygen and titrated naloxone, and the dose philosophy is the core of the topic. Run the ABCDE: open and protect the airway (suction, head tilt, left lateral position; intubate only if ventilation cannot be maintained or naloxone fails), give high-flow oxygen to the hypoxaemic patient, and establish intravenous access. The definitive reversal is naloxone 400 micrograms intravenously, repeated every two to three minutes and titrated to an adequate respiratory rate and oxygen saturation rather than to full wakefulness. The opioid-tolerant patient who is fully reversed will be pitched into acute withdrawal, with vomiting, agitation, tachycardia and pain, and may develop non-cardiogenic pulmonary oedema from the catecholamine surge, so the endpoint is a patient who breathes at 12 to 14 per minute and oxygenates well, even if they remain drowsy.[1]

When intravenous access cannot be obtained, naloxone 800 micrograms intramuscularly (or the intranasal preparation) is the alternative, with onset in five to ten minutes and a longer duration. For the patient who re-narcotises — typically the methadone, sustained-release oxycodone or fentanyl-patch overdose — a naloxone infusion is started at two-thirds of the effective bolus dose per hour (for example, if 1.2 milligrams intravenously restored ventilation, infuse 0.8 milligrams per hour), titrated to maintain an adequate respiratory rate for at least 12 hours after the last opioid dose because methadone has a half-life of 24 to 60 hours.[3]

Activated charcoal 50 grams (one gram per kilogram) is given only to the patient who is awake, protecting their airway and within one to two hours of an oral opioid — it is never prioritised over naloxone and never given to the obtunded patient without a protected airway. Whole-bowel irrigation is reserved for the body-packer or the sustained-release formulation. Hypotension responds to intravenous crystalloid and to naloxone reversal; an inotrope is rarely needed. Intubation is reserved for the patient who cannot be ventilated, who has failed an adequate naloxone trial, or who has a co-ingestant or a structural lesion requiring airway control. [1]

Naloxone pharmacology and the dosing strategy

Naloxone is a competitive mu-opioid-receptor antagonist with a rapid onset (one to two minutes intravenously), a short half-life of 60 to 90 minutes, and a duration of action of 20 to 90 minutes — shorter than every long-acting opioid and most sustained-release formulations, which is why re-narcotisation is the rule rather than the exception for methadone and the fentanyl patch. The drug has no agonist activity and is essentially inert in the opioid-naive patient, which makes it safe to give as a diagnostic challenge — but in the opioid-tolerant patient it displaces the opioid from the receptor and precipitates acute withdrawal, with vomiting, agitation, piloerection, tachycardia, pain and a catecholamine surge that may generate non-cardiogenic pulmonary oedema. The dosing strategy therefore splits into two philosophies that the candidate must hold simultaneously: the higher-dose empirical reversal (0.4 mg IV, repeated) for the opioid-naive or the respiratory-arrest patient, and the low-dose titrated reversal (0.04 to 0.1 mg IV, repeated) for the opioid-tolerant chronic user in whom the goal is ventilation, not wakefulness.[1]

Definitive management and escalation

Definitive care is the maintenance of adequate ventilation for the full duration of the opioid's action, and the escalation ladder is built around the duration of the agent. For a short-acting heroin or fentanyl overdose, the patient who responds to one or two naloxone boluses and remains well is observed for at least two hours after the last naloxone dose, because naloxone's half-life (60 to 90 minutes) outlasts the opioid and re-narcotisation is the risk. For methadone, sustained-release oxycodone and the fentanyl patch, a single bolus is never sufficient: the opioid re-enters the circulation from a deep compartment as naloxone is cleared, and a naloxone infusion at two-thirds of the effective bolus per hour (titrated to the respiratory rate) is continued for at least 12 hours, often longer for methadone.[3] For buprenorphine, which binds the mu receptor tightly, higher cumulative naloxone doses may be required and the patient who does not respond to 2 milligrams of naloxone needs airway support rather than escalating boluses.

The two errors to refuse are an over-large naloxone bolus and a too-short observation. Over-reversal precipitates acute withdrawal, agitation, vomiting and aspiration, and a sympathetic surge that generates non-cardiogenic pulmonary oedema; naloxone is titrated, not dumped. Under-observation discharges a methadone or sustained-release patient who re-narcotises at home; the observation period is dictated by the agent, not by how well the patient looks after the first bolus. [1]

Subtypes and specific scenarios

The exam-favoured distinctions are five. Fentanyl and the synthetic opioids (sufentanil, carfentanil) are extraordinarily potent and may cause chest-wall rigidity that makes bag-mask ventilation difficult, rapid apnoea, and a requirement for higher cumulative naloxone doses; transdermal fentanyl continues to deliver drug and the patch must be removed and the skin washed. Methadone is the long-acting trap: a half-life of 24 to 60 hours, QT prolongation with torsades risk, and re-narcotisation hours after a bolus — the naloxone infusion is mandatory and the observation is prolonged. Tramadol is serotonergic and lowers the seizure threshold: the opioid-overdose patient who is tremulous, agitated, hyperreflexic and clonus-positive has serotonin syndrome and needs benzodiazepines, cooling and (for moderate-to-severe cases) cyproheptadine, not escalating naloxone; seizures are treated with a benzodiazepine.[2] Heroin (diamorphine), usually injected or inhaled ('chasing the dragon'), is the classic short-acting overdose and the archetype of the naloxone-responsive toxidrome, with non-cardiogenic pulmonary oedema as its signature complication. The body-packer (swallowing packets for transport) presents with intestinal obstruction or packet rupture and massive toxicity; whole-bowel irrigation, imaging and surgical consultation are added to naloxone. The patient found down for a prolonged period develops the secondary complications of immobility — rhabdomyolysis, compartment syndrome and pressure injury — that dominate the later course.

Complications and pitfalls

The complications are the consequences of respiratory depression and immobility, and the candidate must link each to its mechanism. Aspiration of gastric contents follows the loss of airway reflexes in the obtunded patient and may proceed to aspiration pneumonitis and pneumonia; airway protection and the left lateral position are preventive. Non-cardiogenic pulmonary oedema develops in a fraction of heroin and other opioid overdoses, both before and after naloxone — the mechanism is a capillary-leak and catecholamine surge, and it is treated with oxygen and positive-pressure ventilation (non-invasive or invasive), not with diuresis.[4] Rhabdomyolysis follows prolonged immobility and muscle compression, with a rising creatine kinase and a risk of acute kidney injury; intravenous fluids and monitoring of the creatine kinase and renal function are the management. Compartment syndrome is the limb-threatening end of the same prolonged-immobility picture and demands a high index of suspicion and surgical decompression. Acute withdrawal is precipitated by over-reversal with naloxone and is the most common iatrogenic complication. The pitfalls are the inverse of the management: pushing naloxone to full consciousness; failing to start an infusion for methadone; discharging the long-acting patient too early; missing a co-ingestant or a pontine lesion in the naloxone non-responder; and forgetting the secondary complications of the prolonged-down patient.[3][4]

Prognosis and disposition

The prognosis is excellent for the patient who is reversed before a cardiac arrest: survival with full neurological recovery is expected, because the mechanism is reversible receptor blockade rather than structural injury. Death, when it occurs, is from hypoxic cardiac arrest in the patient who presented late or was found down, or from aspiration and pulmonary oedema. The disposition turns on the agent. The short-acting overdose (heroin, immediate-release oxycodone, fentanyl by injection) that responds to one or two naloxone boluses is observed for a minimum of two hours after the last naloxone dose; if ventilation and consciousness are stable, the patient is discharged to psychiatric or addiction care. The long-acting overdose (methadone, sustained-release oxycoxone, the fentanyl patch) is admitted to a monitored bed for a minimum of 12 hours on a naloxone infusion, because re-narcotisation is the rule. Any patient requiring intubation, an infusion or more than two boluses goes to a high-dependency or intensive care bed. Take-home naloxone and overdose-prevention education are offered at discharge. [1]

Special populations

The opioid-tolerant patient (chronic opioid therapy, methadone or buprenorphine maintenance) is the patient most at risk of over-reversal: naloxone is titrated with particular care to ventilation, and full reversal is avoided because it precipitates a severe withdrawal that the patient will not forgive. The opioid-naive elderly patient, started on a therapeutic opioid for pain, is exquisitely sensitive and may present with toxicity from a single prescribed dose; the dose is reduced, the agent is reviewed, and naloxone is titrated gently. The paediatric ingestion — a child who finds a grandparent's oxycodone or a methadone tablet — is a medical emergency, because opioid-naive children develop toxicity at adult doses and methadone is frequently fatal; naloxone is weight-based (10 to 20 micrograms per kilogram) and the observation is prolonged. The pregnant patient is managed identically — naloxone is not teratogenic and the maternal circulation is resuscitated first, because the foetus dies if the mother is hypoxic. The body-packer is admitted for the whole duration of the packet transit with imaging surveillance. [1]

Evidence and regional guidelines

The contemporary framework is built on titrated naloxone as the universal reversal agent, with route and infusion strategy dictated by the agent and the clinical setting. The evidence-based guidelines for naloxone administration consolidate the titrated-dose philosophy and the intramuscular alternative when intravenous access is delayed.[1] Tramadol's serotonergic and pro-convulsant profile, and its capacity to generate serotonin syndrome in overdose, is documented in the case literature and is the basis for treating the agitated opioid patient with benzodiazepines rather than escalating naloxone.[2] The prolonged toxicity of methadone, and its requirement for a naloxone infusion and non-invasive ventilation for the pulmonary complication, is illustrated in the methadone-induced acute respiratory distress syndrome reports.[3] The non-cardiogenic pulmonary oedema, rhabdomyolysis and myocardial injury that complicate heroin overdose are documented together in the heroin-inhalation case literature and frame the secondary-complication management.[4]

Exam practice

Exam pearls

• The triad is coma, pin-point pupils (miosis) and reduced rate AND depth of breathing — and it is opioid toxicity until proven otherwise.
• Naloxone 400 micrograms intravenously, repeated every 2 to 3 minutes, titrated to a respiratory rate of 12 to 14 and a good saturation — NOT to full consciousness. A breathing but drowsy patient is correctly managed.
• No intravenous access: naloxone 800 micrograms intramuscularly (or intranasal), onset 5 to 10 minutes.
• Long-acting opioids (methadone, sustained-release oxycodone, fentanyl patch): naloxone infusion at two-thirds of the effective bolus per hour, for 12 hours or more — methadone has a 24 to 60 hour half-life and a single bolus will wear off.
• The naloxone non-responder does not have a pure opioid overdose — check glucose, look for a co-ingestant (tricyclic QRS, benzodiazepine) or a structural lesion (pontine haemorrhage), and consider clonidine.
• Tramadol is serotonergic and pro-convulsant: the agitated, tremulous, clonus-positive opioid patient has serotonin syndrome — treat with benzodiazepines and cooling, not more naloxone.
• Complications: aspiration, non-cardiogenic pulmonary oedema (oxygen and positive-pressure ventilation, not diuretic), rhabdomyolysis, and compartment syndrome from prolonged immobility.
• Over-reversal precipitates acute withdrawal, vomiting and a catecholamine-driven pulmonary oedema — titrate, do not dump.
• For the opioid-tolerant patient, start low — naloxone 0.04 mg (40 micrograms) IV titrated every 2 to 3 minutes to a respiratory rate above 12, to avoid precipitating acute withdrawal and catecholamine-driven pulmonary oedema.
• Remove the fentanyl patch immediately and wash the skin — the drug depot in the skin keeps releasing for up to 17 hours; start a naloxone infusion.
• Wooden chest syndrome (fentanyl rigidity) can defeat bag-valve-mask ventilation — be ready to paralyse and intubate; the rigidity is partially naloxone-responsive.
• Activated charcoal ONLY if the airway is protected and ingestion was within 1 hour — never prioritise it over naloxone, never in the obtunded unprotected patient.
• Check a bedside glucose on every comatose patient — hypoglycaemia is the great mimic and is rapidly reversible.
• Capnography is the earliest objective sign — the rising end-tidal carbon dioxide precedes the falling saturation in the pre-oxygenated patient.
• Buprenorphine, a high-affinity partial agonist, may need higher cumulative naloxone doses; if no response to 2 mg, switch to airway support rather than escalating boluses.
• Methadone prolongs the QT — check the ECG and the potassium and magnesium; torsades risk rises at higher doses and with co-ingested QT-prolonging drugs.
• Nitazenes and the high-potency fentanyl analogues may require higher cumulative naloxone and repeated dosing — do not be reassured by a single reversal.
• The body-packer presents with packet rupture and massive toxicity or intestinal obstruction — whole-bowel irrigation, imaging and surgical consultation, alongside naloxone.
• Offer take-home naloxone and overdose-prevention education at discharge — community naloxone distribution reduces opioid-overdose mortality.
• In the unknown overdose, the pupil is the single most discriminating sign — miosis narrows the field to opioid, clonidine, the pontine lesion and the cholinergic syndrome. [1]

Red flags